Our Pricing

Understanding BNF Mounjaro Side Effects & Safety

Understanding mounjaro side effects UK BNF data is essential before starting tirzepatide treatment. The British National Formulary (BNF) provides the most authoritative UK reference for prescribers and patients, outlining the complete safety profile of Mounjaro based on clinical trial evidence and post-marketing surveillance. At Cured Pharmacy, our UK-registered clinical team uses BNF guidance to assess suitability and support patients throughout their weight loss journey with Mounjaro, available from £135.00 following a free online consultation.

Common Mounjaro Side Effects According to BNF Data

The BNF classifies Mounjaro side effects by frequency, with gastrointestinal reactions being the most commonly reported. In the SURMOUNT-1 trial, nausea occurred in up to 29% of patients on the 15mg maintenance dose, whilst vomiting affected approximately 11% and diarrhoea occurred in 23% of participants [1]. These effects are typically mild to moderate in severity and diminish significantly after the first 4-8 weeks of treatment.

Other common side effects documented in the BNF include decreased appetite (which contributes to the medication's weight loss mechanism), constipation, abdominal discomfort, and dyspepsia [1]. Fatigue and injection site reactions occur in fewer than 10% of patients. The BNF notes that starting at the lowest 2.5mg dose and escalating gradually every four weeks minimises the intensity of gastrointestinal symptoms.

Most patients at Cured Pharmacy report that side effects are manageable with simple dietary modifications and adequate hydration. Our clinical team provides detailed guidance on symptom management strategies during your consultation, ensuring you're prepared for the initial adjustment period.

Serious Adverse Effects and BNF Safety Warnings

The BNF includes important safety warnings for Mounjaro that all prescribers must consider before initiating treatment. Acute pancreatitis, whilst rare (occurring in fewer than 0.1% of patients), represents a serious potential complication that requires immediate medical attention [2]. Patients should be counselled to recognise symptoms including severe persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting.

Hypoglycaemia risk increases when Mounjaro is used alongside insulin or sulfonylureas, though the medication carries minimal hypoglycaemia risk when used as monotherapy for weight management [2]. The BNF recommends dose reduction of concomitant insulin secretagogues when starting tirzepatide. Gallbladder disorders, including cholelithiasis and cholecystitis, have been reported in clinical trials at rates of approximately 1.5%, likely related to rapid weight loss rather than direct drug effects [1].

Thyroid C-cell tumours were observed in rodent studies, leading to a BNF contraindication in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. Whilst no causal relationship has been established in humans, prescribers at Cured Pharmacy conduct thorough medical history assessments to identify any contraindications before approving treatment.

When to Seek Immediate Medical Attention

The BNF advises patients to discontinue Mounjaro and seek urgent medical care if they experience severe abdominal pain, persistent vomiting preventing oral fluid intake, signs of pancreatitis, or symptoms of thyroid tumours such as a neck lump or persistent hoarseness. Our clinical team at Cured Pharmacy provides clear safety guidance with every prescription, ensuring patients understand warning signs that require immediate assessment.

Managing Gastrointestinal Side Effects: Evidence-Based Strategies

Clinical experience with thousands of UK patients has identified effective strategies for managing the most common mounjaro side effects UK BNF data describes. For nausea, eating smaller, more frequent meals rather than three large meals significantly reduces symptom severity. Avoiding high-fat, fried, or heavily spiced foods during the first month of treatment helps minimise gastrointestinal distress.

Adequate hydration is essential, particularly for patients experiencing vomiting or diarrhoea. The BNF recommends maintaining fluid intake of at least 2 litres daily, using oral rehydration solutions if symptoms are pronounced. Ginger tea, peppermint, and eating slowly whilst chewing thoroughly have shown benefit in patient-reported outcomes, though these approaches lack formal trial evidence [1].

If symptoms persist beyond the initial 8-week adjustment period or significantly impact quality of life, your prescriber may recommend remaining at your current dose for an additional four weeks before escalating. At Cured Pharmacy, our clinical team monitors your progress and adjusts treatment plans based on individual tolerance and response, ensuring optimal outcomes whilst maintaining safety.

Dietary Modifications During Dose Escalation

The BNF notes that side effect intensity often peaks during the 48-72 hours following each dose increase. Planning your injection day to allow rest and dietary flexibility during this window can improve tolerability. Focusing on bland, easily digestible foods such as plain rice, toast, bananas, and lean proteins during escalation weeks helps many patients manage gastrointestinal reactions more effectively.

BNF Contraindications and Precautions for Mounjaro

The BNF lists absolute contraindications for Mounjaro including hypersensitivity to tirzepatide or any excipients, personal or family history of medullary thyroid carcinoma, and Multiple Endocrine Neoplasia syndrome type 2 [2]. These contraindications are non-negotiable and must be screened during every clinical assessment.

Relative precautions require careful prescriber evaluation. Patients with severe gastrointestinal disease, including inflammatory bowel disease or gastroparesis, may experience worsening symptoms due to Mounjaro's effect on gastric emptying [2]. The BNF advises caution in patients with renal impairment, particularly if experiencing significant vomiting or diarrhoea that could precipitate acute kidney injury through dehydration.

Pregnancy and breastfeeding represent important safety considerations. The BNF recommends discontinuing Mounjaro at least two months before planned conception due to the long half-life of tirzepatide and lack of human pregnancy data [2]. At Cured Pharmacy, our consultation process includes comprehensive screening for all BNF-listed contraindications and precautions, with superintendent pharmacist Tarun Kumar overseeing clinical governance to ensure prescribing safety.

Mounjaro vs Wegovy Side Effects: Comparative BNF Analysis

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are listed in the BNF as GLP-1 receptor agonists for weight management, sharing similar side effect profiles dominated by gastrointestinal reactions. However, comparative trial data suggests important differences in tolerability. In head-to-head analysis, tirzepatide demonstrated lower discontinuation rates due to adverse events compared to semaglutide at equivalent efficacy doses [3].

Nausea rates appear comparable between the two medications (29% for Mounjaro 15mg vs 27% for Wegovy 2.4mg in respective trials), but vomiting may be slightly less frequent with tirzepatide [1][3]. Both medications carry similar warnings regarding pancreatitis, gallbladder disease, and thyroid C-cell tumours in the BNF monographs. The dual GIP/GLP-1 mechanism of Mounjaro may offer theoretical advantages in glucose metabolism and lipid profiles, though long-term comparative safety data remains limited.

At Cured Pharmacy, we offer both Mounjaro from £135.00 and Wegovy from £135.00 with pricing transparency before your consultation. Your UK prescriber will discuss the comparative benefits and side effect profiles of each option based on your individual medical history, previous treatment responses, and personal preferences to determine the most appropriate choice.

Switching Between GLP-1 Medications

The BNF does not provide specific guidance on switching between tirzepatide and semaglutide, but clinical practice suggests allowing a washout period equivalent to five half-lives (approximately 25 days for semaglutide, 30 days for tirzepatide) minimises overlapping side effects. Your prescriber at Cured Pharmacy can advise on appropriate transition protocols if you're considering switching medications due to tolerability or efficacy concerns.

Long-Term Safety Profile and Post-Marketing Surveillance

The BNF incorporates data from ongoing post-marketing surveillance, with Mounjaro having been used by over one million patients globally since its 2022 approval. Long-term safety data from the SURMOUNT trials extending to 72 weeks show no unexpected safety signals emerging beyond the initial treatment period [1]. Gastrointestinal side effects typically resolve or significantly diminish after 12-16 weeks, with most patients achieving stable tolerance at their maintenance dose.

Cardiovascular safety represents a critical consideration for any weight loss medication. The MHRA has approved Mounjaro based on favourable cardiovascular risk profiles observed in clinical trials, though dedicated cardiovascular outcomes trials for tirzepatide in obesity populations remain ongoing [2]. Current BNF guidance notes no increased cardiovascular risk compared to placebo, with some trial data suggesting potential cardiovascular benefits through weight reduction and metabolic improvements.

At Cured Pharmacy, we maintain ongoing clinical monitoring for all patients on long-term Mounjaro treatment. Our UK-registered clinical team stays current with MHRA safety alerts and BNF updates, ensuring any new safety information is promptly communicated to patients. All prescription medications at Cured Pharmacy are UK-licensed and sourced through regulated supply chains, guaranteeing product authenticity and quality.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/14395
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine that must be prescribed following a clinical consultation to assess suitability and screen for contraindications listed in the British National Formulary.